Matrix Private Capital Group’s iShares Biotechnology ETF IBB Stock Holding History

Matrix Private Capital Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.1K	Hold	400	–	–	0.03%	110
2026 Q1	$67.5K	Hold	400	–	–	0.03%	110
2025 Q4	$67.5K	Hold	400	–	–	0.03%	112
2025 Q3	$57.7K	Hold	400	–	–	0.03%	110
2025 Q2	$50.6K	Hold	400	–	–	0.03%	113
2025 Q1	$51.2K	Hold	400	–	–	0.03%	118
2024 Q4	$52.9K	Hold	400	–	–	0.03%	129
2024 Q3	$58.2K	Hold	400	–	–	0.03%	129
2024 Q2	$54.9K	Hold	400	–	–	0.03%	129
2024 Q1	$54.9K	Hold	400	–	–	0.04%	124
2023 Q4	$54.3K	Hold	400	–	–	0.04%	121
2023 Q3	$49K	Hold	400	–	–	0.04%	135
2023 Q2	$50.8K	Hold	400	–	–	0.04%	138
2023 Q1	$51.7K	Buy	+400	New	+$52.4K	0.04%	156

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Matrix Private Capital Group's IBB Position: Q2 2026 in Review

Matrix Private Capital Group held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 400 shares worth $76.1K. The position accounts for 0.03% of the portfolio, ranked #110.

Matrix Private Capital Group first reported a position in IBB in Q1 2023 and has held it in 14 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Matrix Private Capital Group held 400 shares of iShares Biotechnology ETF worth $76.1K as of Q2 2026.
Matrix Private Capital Group left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.03% of Matrix Private Capital Group's portfolio in Q2 2026, its #110 holding.
Matrix Private Capital Group first reported a position in iShares Biotechnology ETF in Q1 2023 and has held it in 14 quarters since.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Matrix Private Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.